[Characterization of FVIII/VW circulating after DDAVP administration (author's transl)].
These studies were designed with the purpose of providing more information relevant about the new FVIII/VW circulating after administration intranasally DDAVP. One health subject was administered 260 microliter total dose of DDAVP. The newly released FVIII/VW could not be distinguished form circulating FVIII/VW on the basis of molecular size, electrophoretic mobility or "in vitro" stability of VIII:C and VIIIR:AG despite apparent differences in the duration of response of the procoagulant and antigenic components "in vivo". FVIII/VW cryoethanol-precipitations studies showed similar increase in the high molecular weight (HMW) and low molecular weight (LMW) after DDAVP administration. This suggest a immediately polymerization in the new VIIIR:AG circulating after DDAVP administration.
D000281:Administration, Intranasal; D001127:Arginine Vasopressin / Q000276:immunology / Q000302:isolation & purification; D001779:Blood Coagulation Factors; D002850:Chromatography, Gel; D003378:Counterimmunoelectrophoresis; D003894:Deamino Arginine Vasopressin / Q000276:immunology / Q000302:isolation & purification; D005169:Factor VIII / Q000276:immunology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D008970:Molecular Weight; D013696:Temperature; D014841:von Willebrand Factor
D001779:Blood Coagulation Factors; D014841:von Willebrand Factor; D001127:Arginine Vasopressin; D005169:Factor VIII; D003894:Deamino Arginine Vasopressin
Caracterización del FVIII/VW circulante tras la administración de DDAVP.